FMP
Astria Therapeutics, Inc.
ATXS
NASDAQ
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
9.55 USD
0.2 (2.09%)
About
ceo
Ms. Jill C. Milne Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.astriatx.com
exchange
NASDAQ
Description
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
CIK
0001454789
ISIN
US04635X1028
CUSIP
04635X102
Address
100 High Street
Phone
617 349 1971
Country
US
Employee
59
IPO Date
Jun 25, 2015
Key Executives
